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Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the
veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of
clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics,
identification of panel members with the expertise to draft the statements, and other aspects of assuring
the integrity of the process. The statements are derived from evidence-based medicine whenever possible
and the panel offers interpretive comments when such evidence is inadequate or contradictory. A draft is
prepared by the panel, followed by solicitation of input by the ACVIM membership which may be incor-
porated into the statement. It is then submitted to the Journal of Veterinary Internal Medicine, where it
is edited before publication. The authors are solely responsible for the content of the statements.
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This report represents a scientific and working clinical consensus statement on seizure management in dogs based on cur-
rent literature and clinical expertise. The goal was to establish guidelines for a predetermined, concise, and logical sequential
approach to chronic seizure management starting with seizure identification and diagnosis (not included in this report),
reviewing decision-making, treatment strategies, focusing on issues related to chronic antiepileptic drug treatment response
and monitoring, and guidelines to enhance patient response and quality of life. Ultimately, we hope to provide a foundation
for ongoing and future clinical epilepsy research in veterinary medicine.
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Epileptic seizures are a common neurologic disorderin dogs characterized by a wide spectrum of clinical
signs and consequences. Variable short- and long-term
morbidity effects occur caused both by the disease and
its treatment. Survivability often is dependent more on
quality of life and financial issues than actual disease
manifestations.1,2 As such, the burden is on the clinician
to balance the variable outcome measures of seizure
control and owner perception of patient quality of life.
Epilepsy is a heterogeneous disease process compli-
cated by the inability to obtain a definitive diagnosis for
all patients as a consequence of the challenges of limited
diagnostic testing because of financial constraints, unpre-
dictability of disease progression, and gaps in scientific
knowledge of disease pathophysiology.3–5 Lack of unifor-
mity of accepted definitions for seizure type, diagnosis,
and treatment are being addressed but are complicated
by wide variations in treatment strategies between pri-
mary and specialty clinicians alike. Furthermore, a rela-
tively small database of strong evidence-based clinical
studies exists for the ever-changing number of antiepilep-
tic drugs (AED) designed for human use. As a result,
many primary care clinicians are left to treat epilepsy
with lack of uniform, scientifically based guidelines.
The International Veterinary Epilepsy Task Force
recently published collaborative consensus statements
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on epilepsy classification3, diagnostic approaches,6 treat-
ment,7 and therapeutic outcome measures.4 These
papers have created a working foundation for the
advancement of veterinary epileptology.
The purpose of this paper was to build on previous
work by providing a scientific and working clinical con-
sensus statement on seizure management in dogs based
on current literature coupled with clinical expertise. The
goal is to establish guidelines for a predetermined, con-
cise, and logical sequential approach to seizure manage-
ment starting with seizure identification and diagnosis
(not included in this report), reviewing decision-making,
treatment strategies, focusing on issues related to
chronic AED treatment response and monitoring, and
concluding with guidelines to enhance patient response
and quality of life. Ultimately, we hope to provide a
foundation for ongoing and future clinical epilepsy
research in veterinary medicine.
Methodology
The consensus was reached based on the available
published evidence in the peer-reviewed literature,
including proceedings of Annual Congresses of the
European Society and College of Veterinary Neurology
(ESVN ⁄ ECVN) and the American College of Veteri-
nary Internal Medicine (ACVIM). Aside from searching
the standard electronic databases Pub Med (www.ncbi.
nlm.nih.gov/PubMed), CAB Abstracts (www.cabdirect.
org), and Web of Science (http://wok.mimas.ac.uk),
search strategies included reference lists of published
papers and proceedings of the aforementioned relevant
scientific conferences. Studies were included following
modified criteria previously laid out in detail.8 and
included any peer-reviewed study without language
restrictions in which an AED was used and dogs were
diagnosed with presumptive idiopathic epilepsy. The
diagnosis of idiopathic epilepsy was considered likely
when the dogs were between the ages of 6 months and
6 years, had no interictal neurologic deficits, and meta-
bolic causes were excluded.9–11 Advanced brain imaging
(magnetic resonance imaging [MRI], computer tomog-
raphy [CT]), cerebrospinal fluid (CSF) analysis, or some
combination of these was preferable, but not essential.
Data of dogs in which epilepsy was caused by an identi-
fiable cause were not considered. Any form of treat-
ment, including medical and alternative therapies (see
supplementary file), were included in this statement.
The ACVIM consensus panel based its recommendation
for clinical practice on the current published evidence
using the criteria with 4 levels of recommendations
based on scientific merit and expert panel consensus8,12
(Table 1).
When Should Treatment Be Started?
The decision to start AED treatment is based on a
number of factors, including etiology, risk of recur-
rence, seizure type, tolerability, and adverse effects. Risk
factors for seizure recurrence are not well established
for cats and dogs. A number of relative risk factors
have been identified in epileptic people, including a
diagnosis of current or previously defined cerebral
lesions or trauma, presence of interictal EEG epileptic
discharges (up to 90% recurrence rate) and a history of
marked postictal adverse effects.13,14 Evidence-based
guidelines from several international groups are well
established for people based on risk-benefit ratio and
predictability factors of drug effect.15–17 From these
guidelines, several commonalities exist in guiding clini-
cal practice including confirmation of an epileptic sei-
zure event and seizure type, obtaining a definitive
diagnosis, knowledge that recurrent seizure activity is
correlated with poorer long-term treatment success,
and the influence of treatment on quality-of-life
(QOL) factors.18 Thus, the decision to treat is a
reflection of the treatment goals to decrease or elimi-
nate epileptic events, decrease seizure severity, avoid
adverse effects, and decrease seizure-related mortality
and morbidity.7,19,20
Although similar information is not as readily avail-
able for dogs, extrapolation can provide rational treat-
ment guidelines. Overwhelming evidence exists in
people that there is no benefit to starting treatment
after a single unprovoked event.14 The earlier AED
treatment is started; however, the better the potential
outcome may be for seizure control.21–23 Recurrent
epileptic seizures can increase epileptogenesis and drug
resistance in a subgroup of patients.24,25 Prolonged
and acute repetitive seizures can increase patient mor-
bidity and require prolonged hospitalization with asso-
ciated financial burden. Comparable information is not
available for dogs.
The panel recommendations to initiate AED treat-
ment are summarized as follows: (i) Identifiable struc-
tural lesion present or prior history of brain disease or
injury; (ii) Acute repetitive seizures or, status epilepticus
(ictal event ≥5 minutes or ≥3 or more generalized sei-
zures within a 24-hour period); (iii) ≥2 or more seizure
events within a 6-month period; and (iv) Prolonged,
severe, or unusual postictal periods.
Which Drug Should Be Used First?
Selection of AED is based on a number of factors,
including seizure type, efficacy, and tolerability. No evi-
dence exists that any single AED provides a better out-
come for adults with unprovoked epilepsy when early
treatment is started in people.18 Drug selection, there-
fore, is often based on tolerability in both people and
dogs. The panel recommendations are summarized in
Table 1.
Phenobarbital
Phenobarbital is a phenyl barbiturate with the longest
history of chronic use of all AEDs in veterinary medi-
cine. Phenobarbital has high bioavailability, being
rapidly absorbed within 2 hours and with maximal
plasma concentration being achieved within 4–8 hours
after PO administration.26 Approximately 50% of the
drug is protein bound. The majority of phenobarbital is
478 Podell et al
metabolized by the liver, with approximately one third
excreted unchanged in the urine. Phenobarbital is an
auto-inducer of hepatic microsomal enzymes (p450 sys-
tem), which can progressively decrease the elimination
half-life with chronic dosing.26–28 Overall, phenobarbital
is a relatively inexpensive, well-tolerated drug that can
be administered twice daily at a starting dosage of
2.5 mg/kg PO q12 h.26
Variable monotherapy efficacy for seizure reduction
was evaluated in 8 studies for a total of 311 dogs.29–35
Twenty or more dogs were evaluated in each of 5 stud-
ies31–35 evaluating a total of 289 dogs treated from 5 to
32 months in 3 of the studies31,32,35 with undocumented
duration in 2 studies29,33 The cumulative success rate of
>50% seizure reduction to improve seizure control was
82% (258/311 dogs), with a cumulative seizure-free rate
of 31% (93/311) and failure rate (no improvement) of
15% (48/311).
Potassium Bromide
Bromide was the first documented AED used for
epilepsy in people in 1857 with introduction to veteri-
nary medicine in the 1980s. Bromide typically is given
as the inorganic salt potassium bromide, usually as a
solution of 200–250 mg/mL dissolved in double-distilled
water. In the United Kingdom, several approved com-
mercial formulations are available. A starting dosage of
40 mg/kg/day potassium bromide is recommended.
Bromide is slowly metabolized in the dog with median
elimination half-life of 15.2 days and steady-state con-
centrations of 2450 mg/l. The apparent total body
clearance is 16.4 mL/kg/day and the volume of distri-
bution is 0.40 L/kg.36 Steady-state concentrations fluc-
tuate among dogs, most likely as a result of individual
differences in clearance and bioavailability. Dietary fac-
tors also alter serum drug concentrations, with high
chloride diets resulting in excessive renal excretion and
lower serum concentrations.37 The drug is excreted in
the urine without known hepatic metabolism or
toxicity.
Evaluation of bromide monotherapy efficacy was
found in only a single study34 in which 73.9% (17/23)
of dogs had > 50% seizure reduction and 52% (12/23
dogs) were seizure- free during the 6-month treatment
period. The remaining studies focused on the efficacy of
potassium bromide as an additional drug with pheno-
barbital, primidone, or both.31,32,34,38–40
Table 1. ACVIM panel recommendations of AED use, monitoring, and risk profile.
Drug
Monotherapy
recommendation
Monitor drug levels
Risks Add-on AED
recommendationTypes
Level Grade 1 2 3 4 Level Grade
Phenobarbital I A Y Y Y Y N IV B
Bromide I B Y Y Y Y N II B
Primidone II D Y Y Y Y N II D
Imepitoin I A N Y N N N III C
Levetiracetam IV C N Y N N N Ib B
Zonisamide III C Y Y Y N N III B
Level of study design
Level I and Ib Appropriately designed, controlled trials
1 Criteria
a I: Blinded, randomized clinical trials and drug efficacy of ≥50% for at least 6 months
b Ib: Blinded, randomized clinical trials and drug efficacy of ≥50% for less than 6 months
Level II: Case-control or cohort studies
1 Criteria:
a Nonblinded, randomized, or nonblinded and nonrandomized clinical trials with cohort size of 15 or more, drug efficacy of
> or equal to 50% for > 12 weeks, or both.
Level III: Case reports or series
1 Based on individual case reports, conference proceedings, and/or other media distribution as a potentially effective and/or
predictable outcome
2 Criteria:
a Nonblinded and nonrandomized clinical trials with cohort size of less than 15 and/or drug efficacy of ≥50% for
>12 weeks
Level IV: Expert opinion only
1 Based on any level of scientific information as an unestablished, ineffective, and/or harmful
2 Criteria: Expert opinion only without documentation of cohort studies
Grade of ACVIM panel recommendation
1 A: High recommendation and likely be effective treatment
2 B: Moderate recommendation and most likely to be effective treatment
3 C: Low recommendation and may not be effective treatment
4 D: Not recommended for treatment and may be ineffective and/or dangerous to the patient
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Primidone
Primidone is the only AED that is specifically
approved for dogs in the United States, whereas pheno-
barbital, imepitoin, and (as an additional drug) potas-
sium bromide are approved for treatment of epilepsy in
dogs in Europe. Orally administered primidone is
rapidly metabolized to its major active metabolite phe-
nobarbital.41 Experimental studies in dogs indicated
that phenobarbital is responsible for more than 85% of
the total anticonvulsant activity during continued
administration of primidone.41 In a prospective ran-
domized clinical trial, in which the efficacy of phenobar-
bital and primidone against epilepsy in dogs was
compared, 35 dogs with generalized tonic-clonic seizures
were treated for a minimum of 6 months with either
drug.42 Forty percent of the dogs became seizure-free
during treatment with phenobarbital compared to only
25% with primidone. Furthermore, primidone was less
well tolerated in dogs than phenobarbital.30 In a retro-
spective trial in 65 epileptic dogs, primidone and pheno-
barbital were reported to exert similar efficacy, but
important details of study design were not reported.43
In a retrospective comparison of phenobarbital and
primidone in 70 newly diagnosed epileptic dogs with
different causes of epilepsy, in which the animals were
treated for at least 3 months, only 20% of phenobarbi-
tal-treated dogs became seizure-free compared to 15%
of those treated with primidone.32.33 Switching pheno-
barbital-resistant dogs to primidone did not result in
improved seizure control, indicating that there is no
advantage to the use of primidone over the use of phe-
nobarbital for the control of seizures in most dogs.43
Imepitoin
Imepitoin was approved in Europe for treatment of
idiopathic epilepsy only in dogs in 2013, in Australia in
2015 and is currently unavailable in the United States.
Imepitoin has a novel and selective mechanism of action
that potentiates GABAergic inhibition by acting as a
low-affinity, low-efficacy partial agonist at the benzodi-
azepine site of the GABAA receptor, although it differs
in chemical structure from benzodiazepines.44 In a piv-
otal multi-center clinical field trial, imepitoin was com-
pared with phenobarbital in 226 epileptic dogs in a
randomized blinded parallel group design.35 The admin-
istration of imepitoin twice daily in incremental dosages
of 10, 20, or 30 mg/kg was as effective as phenobarbital
in controlling generalized seizures in dogs, but the fre-
quency of adverse events including somnolence or atax-
ia, polydipsia and increased appetite was significantly
higher in the phenobarbital group. These results indi-
cated that imepitoin is a potent and safe first-line AED
for epileptic dogs.
Several other trials have been performed in dogs
including: (i) a randomized controlled blinded trial in
which imepitoin was compared with a pseudoplacebo
(ie, low dose of imepitoin); (ii) a randomized blinded
trial in which imepitoin was compared with primidone;
(iii) an exploratory trial comparing imepitoin with
phenobarbital and primidone in newly diagnosed dogs
with epilepsy; and, (iv) an exploratory trial comparing
added imepitoin with added potassium bromide in dogs
resistant to treatment with phenobarbital or primi-
done.31,32,35,45,46 Overall, >400 dogs were treated in
these trials, and each study identified consistent anticon-
vulsant efficacy for imepitoin.45
Levetiracetam
Levetiracetam was approved by the FDA in 1999 for
treatment of refractory focal onset seizures in adults. The
drug possesses several favorable pharmacokinetic proper-
ties in dogs, including rapid, complete absorption after
PO administration, minimal protein-binding,47 lack of
hepatic metabolism with the drug primarily excreted
unchanged in the urine,48 and a wide safety margin (ie,
high therapeutic index). Levetiracetam is rapidly metabo-
lized, with an elimination half-life between 4 and
8 hours.47 As such, levetiracetam has gained considerable
popularity in veterinary medicine. However, there cur-
rently are no published reports evaluating the use of leve-
tiracetam as first-line treatment in dogs with epilepsy.
Zonisamide
Information on the clinical efficacy of zonisamide
in epileptic dogs is limited to 3 small open-label,
uncontrolled studies, with only a single monotherapy
study.49–51 The only study on the use of zonisamide as
monotherapy for canine idiopathic epilepsy included 10
dogs with generalized-onset seizures receiving zon-
isamide at 5–15 mg/kg PO q12h to achieve serum zon-
isamide concentrations of 10–40 lg/mL.51 Of these
dogs, 60% (6/10) had a ≥ 50% decrease in monthly fre-
quency of seizures with a follow-up of 12–36 months.
The mean zonisamide dosage in these 6 dogs was
7.92  3.79 mg/kg q12h. The remaining 4 dogs had an
unsatisfactory response of unchanged or increased sei-
zure frequency in 2 dogs each, respectively. Mean peak
(3 hours after PO administration) zonisamide serum
concentrations were 15.24  5.95 lg/mL (range, 7.7–
24 lg/mL) in the 6 dogs with favorable response and
22.41  19.69 lg/mL (range, 9.3–51.6 lg/mL) in the 4
dogs with an unsatisfactory response.51
How Should Monitoring Be Performed?
The objectives of monitoring trough serum concentra-
tions of any AED are to: (i) Determine effective drug
concentrations after initiation of successful treatment
(as appropriate); (ii) Determine if drug failure is because
of pharmacokinetic factors so as to focus on a change
in dose (metabolic tolerance) or pharmacodynamic fac-
tors so as to focus on a change of drugs (functional tol-
erance); (iii) Determine if treatment failure is caused by
poor compliance or an inadequate or changed drug
concentration; (iv) Prevent toxic effects; and (v) Aid
with individualization of treatment.52
Optimal comparison of successive drug concentra-
tions is best achieved by evaluating concentrations
480 Podell et al
determined at the same time after dosing. Debate on
the necessity of trough concentration sampling exists.
Trough concentrations are best used when patients are
most likely to seizure just before the next scheduled
dosing for drugs with shortened elimination half-lives,
and if an abnormal drug reaction is suspected.
Chronic AED use necessitates achieving a steady-
state condition, in which a specific drug dose and inter-
val result in a serum concentration that fluctuates
within a reference range.53 This therapeutic range is a
population-based statistical concept whereby the major-
ity of patients will seizure below the lower limit of the
range and the majority of patients will have toxic effects
above the upper limit of the range. Overall, the thera-
peutic range is best determined on an individual basis.
Adjustments are based on each patient’s efficacy and
tolerance response. The panel recommendations are
summarized in Table 2.
Phenobarbital
Serial serum phenobarbital concentrations should be
evaluated at the first steady-state concentration point of
2 weeks and at the steady-state clearance time point of
6 weeks, because enhanced clearance from hepatic auto-
induction can occur.26 Additional monitoring at 6-
month intervals thereafter, if the pet has >2 seizure
events between these times, and at 2 weeks after a
dosage change is recommended. Although blood con-
centration fluctuations may not be dramatic throughout
the day in dogs with steady-state concentrations,54
trough blood samples are best taken in the early morn-
ing, before dosing, in a fasted dog, to increase consis-
tency in comparison with published information,
maintain consistency in interpretation and avoid diurnal
changes or dietary-induced fluctuations in absorp-
tion.55,56 Significantly lower trough compared to non-
trough concentrations were reported in dogs receiving
>10 mg/kg/day of phenobarbital.57
The most efficacious and safe therapeutic range
reported for dogs is 15–35 lg/mL,26,30,58 although effi-
cacy can be seen at lower concentrations. Metabolic tol-
erance is present when progressive dose increases
without concurrent parallel increase in serum drug con-
centration occurs, most likely because of other drugs
that are p450 enzyme inducers or genetic variations.
Conversely, phenobarbital will increase clearance of
several other AEDs, including levetiracetam,59,60
zonisamide61 and clorazepate.62
Bromide
Potassium bromide serum concentration measure-
ments are recommended at the first steady-state concen-
tration point between 6 and 12 weeks then on an
annual basis or if > 3 seizures occur before the next
scheduled evaluation, or if signs of toxicity are sus-
pected. Because of the long elimination half-life, sam-
ples can be collected at any time point >2 h after
dosing to avoid any peak effect variability.63 The
reported therapeutic range is individualized according
to the high variability in patient response and tolerance
to the drug. Studies have shown that bromide concen-
trations between 810 and 2500 lg/mL with phenobarbi-
Table 2. Qualified criteria recommendations for AED drug use.
Drug
Indications
Drug monitoring Cautions and risks Initial dose
Seizure
type
Seizure
etiology Other
Phenobarbital 2 and 6 weeks, q6m, or
2 weeks after dose change;
Range: 15–35 lg/mL
Increases clearance of levetiracetam
and zonisamide
Hepatotoxicity
Idiosyncratic blood
dyscrasia
Necrolytic dermatitis
2.5 mg/kg q12h
Monotherapy All All
Add-on All All
Potassium
Bromide
1 and 3 months, q12m or
1 month after dose change
Range: 1000–3000 mcg/mL (mono)
or 800–2500 mcg/mL with
phenobarbital
Pancreatitis
Sedation
Ataxia
40 mg/kg/day
Monotherapy All Idiopathic Low initial
frequency
Add-on All All Liver
disease
Imepitoin
NR 15 mg/kg q12hMonotherapy All Idiopathic
Add-on NR NR
Levetiracetam
NR Renal disease 20 mg/kg q8hMonotherapy All All Liver
disease
Add-on All All
Zonisamide 2 and 3 months, q6m and
2 weeks after dose change
Range: 10–40 mcg/mL
Idiosyncratic renal and
hepatic disease
5 mg/kg q12h
7–10 mg/kg q12h
with phenobarbital
Monotherapy All All
Add-on All All
NR = not recommended.
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tal combination treatment are effective,34,40,64 whereas
monotherapy efficacy was seen with higher concentrations
up to 3000 lg/mL.34,64 The dosage can be adjusted
according to the formula: (Target Css – Actual Css) 9
(Clearance/Bioavailability) = mg/kg/day added to the
existing dose (where Clearance/Bioavailability = 0.02
and Css = steady-state concentration).
No known drug contraindications have been
reported, and bromide undergoes no hepatic metabo-
lism or protein-binding. Concomitant use of phenobar-
bital can enhance the risk of sedation and weakness.
Clearance may be decreased in dogs with impaired renal
function, resulting in higher steady-state concentrations.
Primidone
As described above, the active metabolite phenobar-
bital is responsible for >85% of the anticonvulsant
effect obtained during treatment of dogs with primi-
done. Thus, primidone treatment can be monitored by
plasma concentrations of phenobarbital.41–43,58 The
therapeutic plasma concentration range of phenobarbi-
tal in dogs treated with phenobarbital or primidone is
the same.30
Imepitoin
Imepitoin has a relatively short half-life in dogs of
approximately 2 hour so that no clinically relevant drug
accumulation develops during prolonged treatment with
clinically used dosages (10–30 mg/kg q12h).45 Further-
more, interindividual differences in half-life are low, the
therapeutic index is high (ie, toxicity is minimal, thus
making rapid dose adjustment less likely to cause
adverse effects) and the therapeutic concentration range
is not known.45 There is no indication that imepitoin
alters the metabolism of other drugs, including AEDs.45
As such, therapeutic drug monitoring is not needed for
monitoring treatment and currently not commercially
available.
Levetiracetam
Serum concentrations of levetiracetam are not rou-
tinely measured in clinical practice, based on the drug’s
wide therapeutic index and lack of an established rela-
tionship between levetiracetam concentrations and both
treatment response and adverse effects in people and
dogs.65 In people, the generally accepted range is 12–
46 lg/mL.53 A reference range for levetiracetam has not
been established in dogs, although the range in humans
often is extrapolated for use in dogs.
There is evidence to support the use of levetiracetam
therapeutic drug monitoring when levetiracetam and
phenobarbital are used in combination. Concurrent
administration of phenobarbital has been shown to alter
the pharmacokinetics of levetiracetam in normal dogs
as well as dogs with epilepsy, resulting in lower peak
concentrations and more rapid elimination.60,66 Moni-
toring levetiracetam serum concentrations in these
instances can help determine whether an increase in
levetiracetam dosage might be warranted in an effort to
optimize treatment on an individual basis. No known
drug-drug interactions have been reported for levetirac-
etam in dogs.
Zonisamide
Zonisamide is metabolized predominantly by hep-
atic enzyme CYP3A4, and coadministration with
other medications that induce or inhibit CYP3A4 that
may change zonisamide pharmacokinetics in people.
Coadministration with phenobarbital (a CYP3A4
inducer) increases zonisamide clearance by approxi-
mately 50% and shortens the elimination half-life.67
In dogs, repeated phenobarbital administration
enhances CYP3A activity,68 but the CYPs involved in
zonisamide metabolism have not yet been established.
It has been shown however that concurrent
administration of zonisamide and phenobarbital alters
zonisamide pharmacokinetics. Repeated PO adminis-
tration of phenobarbital (5 mg/kg q12h for 30–
35 days) decreased the bioavailability, maximum
serum concentration, area under the serum concentra-
tion versus time curve, and apparent elimination half-
life, and increased the total clearance of zonisamide.69
Time to maximum serum concentration and volume
of distribution were not affected by concurrent pheno-
barbital administration. Zonisamide pharmacokinetic
parameters were restored to the same values as before
phenobarbital administration 12 weeks after phenobar-
bital discontinuation.69
Zonisamide does not appear to affect its own metabo-
lism or disposition of other medications because it has
not been shown to induce or inhibit hepatic CYP450
isoenzymes.70 Zonisamide is a weak carbonic anhydrase
inhibitor and therefore caution is warranted when it
must be administered concurrently with other carbonic
anhydrase inhibitors.71
The therapeutic target range for zonisamide of 10–
40 lg/mL in people can be used as guidance regarding
effective concentrations that can be targeted in dogs.
Serum zonisamide concentration should be monitored
1–2 weeks after treatment initiation or dosage adjust-
ment and any time seizure frequency increases. Cur-
rently, there are no recommendations on optimal timing
of blood sampling for zonisamide concentration moni-
toring. In a study assessing both trough and peak serum
zonisamide concentrations in 12 epileptic dogs, all but 1
trough and all peak serum zonisamide concentrations
were within the target range of 10–40 lg/mL but esti-
mated peak zonisamide concentrations were signifi-
cantly higher than trough concentrations.49 In a recent
pharmacokinetic study, fluctuation between peak and
trough concentrations (Cmax and Cmin) was 10% at
steady state.61
The panel recommends collecting a trough sample
within 1 hour before the next scheduled dose to allow
assessment of the lowest concentration that occurs dur-
ing a dosing interval and similar comparison of results
of serial samples. Both trough and peak (3–4 hours
after zonisamide administration) samples should be col-
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lected in dogs with recurrent epileptic seizures concur-
rently on phenobarbital to investigate the potential role
of rapid zonisamide elimination as a cause for therapeu-
tic failure.
What Are The Risks Of Treatment?
Adverse effects can be divided into transient, persis-
tent, and life-threatening categories (either idiosyncratic
or predictable). Most transient adverse effects are avoid-
able with titration dosing and dissipate within several
weeks. Persistent effects are either central nervous sys-
tem (CNS) dose-dependent effects such as sedation,
ataxia, imbalance or cognitive impairment or metabolic-
related with hormonal imbalances, metabolic syn-
dromes, and degenerative effects. Severe life-threatening
effects mainly are associated with either idiosyncratic
bone marrow toxicity (eg, aplastic anemia) or pre-
dictable organ damage over time (eg, hepatotoxicity).
Four categories of adverse effects were established for
each drug:72
Type I: Predictable and directly related to pharmaco-
logic effects in a dose-dependent fashion
Type II: Unpredictable (idiosyncratic) and poten-
tially life-threatening
Type III: Cumulative with long-term treatment and
potentially life-threatening
Type IV: Delayed (carcinogenic or teratogenic) and
life-threatening
The panel conclusions and recommendations are sum-
marized in Tables 1 and 2.
Phenobarbital
Type I: Phenobarbital generally is well tolerated at
the previously mentioned therapeutic serum concentra-
tions in dogs. Behavioral changes, such as hyperex-
citability, restlessness, or sedation, may occur after
starting treatment with the drug, but they appear not to
be dose-related and typically resolve within 1–2 weeks.
Type II: A more serious idiosyncratic reaction is
development of immune-mediated anemia, neutropenia,
thrombocytopenia, or some combination of these,73
with a low prevalence of 4.2% in 1 study.74 Typically,
this reaction occurs within the first 6 months of treat-
ment and is reversible with drug removal and appropri-
ate treatment. Rare acute, idiosyncratic hepatotoxic
reactions may occur also, as evidenced by a rapid
increase of alanine aminotransferase (ALT) activity and
abnormal pre- and postprandial serum bile acid concen-
trations. Phenobarbital also may be a risk factor for
development of superficial necrolytic dermatitis in
dogs.75
Type III: Chronic adverse effects usually affect water
consumption (polydipsia) and appetite (polyphagia). As
a result, dogs may develop psychogenic polydipsia with
associated polyuria. The most common serum biochemi-
cal change with chronic phenobarbital treatment is an
increase in the serum alkaline phosphatase (ALP) activ-
ity,76–78 which can occur as soon as 2 weeks after initi-
ating treatment. Neither endogenous
adrenocorticotropic hormone (ACTH) concentration
nor the response to exogenous ACTH administration is
altered by phenobarbital dosing.79 Moreover, phenobar-
bital does not interfere with the low-dose dexametha-
sone suppression test, regardless of dose or treatment
time.80 Serum total and free thyroxine (T4) concentra-
tions may be low in dogs treated with phenobarbital,
resulting in a mistaken diagnosis of hypothy-
roidism.81,82
A less common but potentially life-threatening com-
plication is drug-induced hepatotoxicity. Documenta-
tion of a serum phenobarbital concentration >35 lg/mL
had the highest correlation with the development of
hepatotoxicity.83 All dogs on chronic phenobarbital
treatment should have a serum biochemistry profile per-
formed every 6 months to monitor for development of
chronic hepatotoxicity followed by a bile acid tolerance
test if altered liver function is suspected.
Type IV: Not reported in the dog.
Bromide
Type I: Potassium bromide generally is well tolerated
in the dog. The most common adverse effects seen with
potassium bromide with or without phenobarbital com-
bination treatment are polydipsia, polyphagia, increased
lethargy, and mild ataxia with increasing serum bro-
mide concentration.84
Type II: Potassium bromide is a known mucosal irri-
tant and capsules may result in gastric irritation because
of direct contact of a concentrated amount of the drug
with the gastric mucosa. Pancreatitis and gastrointesti-
nal intolerance also have been reported.85
Type III: Intoxication to the point of stupor is rare,
but pelvic limb ataxia, weakness, and altered behavior
are more likely with serum concentrations >3000 mg/l.86
Caution should be used when treating dogs with under-
lying renal insufficiency because of decreased renal elim-
ination.87 Treatment for potassium bromide
intoxication consists of IV administration normal saline
to enhance renal excretion.86 Careful monitoring is
advised because dogs may become more susceptible to
seizure activity with lowering of the serum bromide con-
centration.
Type IV: Not reported for the dog.
Primidone
Type I: Treatment with primidone is associated with
adverse effects similar to those documented with pheno-
barbital treatment.
Type II: Treatment with primidone is associated with
adverse effects similar to those documented with pheno-
barbital treatment.
Type III: Increased hepatic enzyme activity is more
frequent and severe with primidone than with pheno-
barbital,30,77,88 which can be explained by assuming that
both intact primidone and its active metabolite pheno-
barbital affect the liver. As a consequence, primidone is
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associated with a higher frequency of hepatotoxicity
than phenobarbital hepatic necrosis, fibrosis and cirrho-
sis all have been associated with chronic use of primi-
done.76,88,89 Therefore, liver enzyme assays and function
tests should be performed every 3–6 months to monitor
for toxicity in dogs.
Type IV: Not reported in the dog.
Imepitoin
Type I: In a safety study under laboratory conditions,
healthy Beagle dogs were given 0, 30, 90, or 150 mg/kg
imepitoin PO q12h for 26 weeks.35 Complete safety
evaluation including histopathology was performed. A
no-observed-adverse-event dosage of 90 mg/kg PO q12h
was obtained, well above the recommended doses for
clinical use of 10–30 mg/kg PO q12h.44,46 In clinical
studies in epileptic dogs, treatment with imepitoin was
associated with relatively mild adverse effects in part of
the animals, including somnolence, sedation, transient
polyphagia, polyuria, polydipsia, and hyperactivity.35,90
Except hyperactivity, all these adverse effects were less
frequent than with phenobarbital.35
Type II: Not reported in the dog.
Type III: No significant alterations in liver enzyme
activity were observed with imepitoin.35 Studies in
healthy dogs indicated that chronic treatment with
imepitoin should not lead to development of tolerance
or dependence, and that abrupt termination of treat-
ment should not result in severe withdrawal effects,
including seizures and status epilepticus.31,44
Type IV: The safety profile of imepitoin was further
characterized in vitro using genotoxicity assays, and in
mice, rats, and dogs with multiple dosing.35,44 Imepitoin
was shown to not be genotoxic, teratogenic, or
immunotoxic.
Levetiracetam
Type I: All of the reported adverse effects associated
with levetiracetam administration in dogs are predictable
and related to its pharmacologic effects in a dose-depen-
dent fashion. Preclinical studies performed on healthy
dogs by the drug manufacturer described unsteady gait,
salivation, vomiting, and sedation with repeated PO dos-
ing at 300–1200 mg/kg/day (5–20 times the recom-
mended dosage for dogs).91 Clinical studies evaluating
the use of levetiracetam as supplemental treatment in
dogs with epilepsy indicated that the drug was well toler-
ated, with infrequent reports of adverse effects.92,93 Seda-
tion, ataxia, restlessness, vomiting, and decreased
appetite have been described, although ataxia was the
only effect shown to differ significantly from baseline in a
randomized, controlled study involving 34 dogs.93
Type II, III, and IV: Not reported in the dog.
Zonisamide
Type I: The reported adverse effects of zonisamide
include sedation, generalized ataxia, vomiting, and inap-
petence.50-52 The prevalence of these adverse effects
varied among studies from 10% (1/10 dogs)51 to 55% (6/
11 dogs)50 Although in some dogs ataxia and sedation
were transient and required no dosage change, in other
individuals a dose reduction was necessary.50,51,5010 Seda-
tion, vomiting, and inappetence resolved in 1 dog after
discontinuation of zonisamide51 As in humans, gradual
titration to final maintenance dosage may help decrease
the frequency and severity of these adverse effects.
Type II: Idiosyncratic reactions to zonisamide are
rare in dogs. As in people, patients with a previous
allergic episode to sulfonamide-containing medications
are at higher risk for developing such reactions.67 Kera-
toconjunctivitis sicca and polyarthropathy (both of
which may be potential adverse effects of sulfonamide-
based medications) were reported in 1 dog each but a
clear cause and effect relationship with zonisamide
administration could not be proven.94
Suspected life-threatening idiosyncratic adverse effects
of zonisamide in dogs include acute toxic hepatopathy
reported in 2 dogs95,96 and renal tubular acidosis
reported in 1 dog.97 Discontinuation of zonisamide
resulted in clinical improvement in 2 of 3 dogs, with 1
dying as a result of hepatopathy.
On the basis of these reports, hepatic enzyme activity,
electrolytes, blood gas analysis, and hematology should
be assessed before initiation of zonisamide and moni-
tored periodically during zonisamide treatment. An
increase in serum chloride concentration and a decrease
in bicarbonate or TCO2 should prompt further investi-
gation of renal tubular acidosis.97
Type III: Zonisamide treatment may affect thyroid
function and some clinical laboratory test results. In a
pharmacokinetic study of healthy dogs given zon-
isamide at 10.3 mg/kg PO q12h for 8 weeks, mean
serum total T4 concentration decreased below the nor-
mal reference range but mean free serum T4 and TSH
concentrations were within the reference range after
6 months of treatment. Increases in serum ALP activity
and serum calcium concentration and decreases in
serum total protein and albumin concentrations were
reported compared to baseline but remained within ref-
erence range.61 A small but statistically significant
decrease in serum albumin concentration and an
increase in ALP activity have been reported in research
dogs given zonisamide at a dosage of 75 mg/kg/day for
52 weeks.98 These studies demonstrate the potential for
zonisamide to cause hepatotoxicity.
Type IV: Not reported in the dog.
When Should a Second AED Be Started and
Which Should be Used?
Epilepsy treatment should be goal-oriented and
approached in an objective fashion. The decision to add
a second AED is based on seizure frequency, severity
(duration, cluster activity, postictal effects), and overall
quality of life. Risk factors associated with poorer seizure
control include male dogs and prior cluster seizure activ-
ity.99 Strict criteria for decision-making strategy on start-
ing a second AED are lacking in veterinary medicine.
Several factors should be considered when deciding on a
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second AED. Selection of an AED with a different mech-
anism of action, minimizing drug-drug interactions,
avoiding additive toxicity, and determination of risk-ben-
efit of polypharmacy versus quality of life are all impor-
tant considerations. A discussion on drug resistance is
provided in a supplementary file. The panel conclusions
and recommendations are summarized in Table 1.
Phenobarbital
With phenobarbital being used predominantly as a
first-line AED in dogs, no studies on its use as a supple-
mental treatment were identified. However, phenobarbi-
tal has been used extensively in combination with
several AEDs, as noted below. Phenobarbital has
important drug-drug interactions with drugs metabo-
lized by the liver that can influence drug concentrations.
Bromide
Concomitant potassium bromide and phenobarbital
administration decreased seizure number and severity in
the majority of dogs in several studies, with seizure-free
status ranging from 21% to 72% of all treated
dogs.39,40,64 These studies, however, were noted to carry
a higher degree of bias.8 By allowing a decrease in the
use of drugs metabolized by the liver, potassium bro-
mide treatment also may decrease the frequency of hep-
atotoxicity.
Primidone
Because primidone has no advantage in efficacy com-
pared to phenobarbital but is associated with a higher
risk potential, especially hepatotoxicity, it should not be
used as a second or alternative drug in dogs in which
monotherapy with phenobarbital, imepitoin, or other
first-line drugs failed. In epileptic dogs that do not
respond to monotherapy with primidone, potassium
bromide has been added, but with only limited thera-
peutic success.31,32
Imepitoin
There is only very limited published information on
supplemental treatment with imepitoin. In a prospective
trial in 17 dogs with chronic epilepsy, in which imepi-
toin was added to the current treatment with phenobar-
bital or primidone, most dogs exhibited decreases in
seizure frequency and severity, and imepitoin was better
tolerated than potassium bromide when used as supple-
mental treatment.31,32 Furthermore, the supplemental
treatment with imepitoin (10–15 mg/kg PO q 12 h) did
not appear to aggravate the CNS-related adverse effects
of phenobarbital or primidone.32
Levetiracetam
To date, all of the published studies on levetiracetam
for dogs with epilepsy have evaluated its use as supple-
mental treatment in dogs refractory to phenobarbital,
bromide, or both. A research abstract described retro-
spective evaluation of 15 dogs with long-standing gener-
alized seizures that were treated with levetiracetam at
PO dosages of 7.1–23.8 mg/kg q8h as part of their
AED regimen.100 A 54% decrease in seizure frequency
over 3 months compared to baseline was reported.
An open-label, prospective, non-comparative trial of
levetiracetam was performed in 14 dogs with idiopathic
epilepsy resistant to phenobarbital and bromide.92 Diag-
nosis of idiopathic epilepsy was based on normal inter-
ictal neurologic examination, exclusion of metabolic
causes, and normal MRI and CSF findings. Levetirac-
etam initially was administered PO at a dosage of
10 mg/kg PO q8h for 2 months with dose escalation to
20 mg/kg PO q8h for 2 months in dogs that experi-
enced a decrease in seizure frequency of <50% from
baseline with no major adverse effects. Nine of 14
(64%) dogs were reported to be ‘responders’, with a
decrease in seizure frequency of > 50%. In the popula-
tion as a whole, a significant decrease in the overall
monthly seizure frequency of 55% and a decrease in sei-
zure days per month of 43% were observed. However,
6 of 9 (67%) responders experienced an increase in sei-
zure frequency and seizure days per month after 4–
8 months of continuing treatment at the last effective
levetiracetam dose.
A randomized, double-blinded, placebo-controlled
cross-over study evaluated 34 dogs refractory to pheno-
barbital and bromide.93 Diagnosis of idiopathic epilepsy
was based on compatible signalment and history, nor-
mal physical and neurologic examinations, and exclu-
sion of metabolic causes. Advanced imaging and CSF
analysis were not required for participation in the
study. After a prospective baseline period of 8 weeks,
dogs were randomized to receive either oral levetirac-
etam (20 mg/kg PO q8h) or matching placebo for
16 weeks. After a 4-week wash-out period, dogs
received the alternate treatment for an additional
16 weeks. As a consequence of a high dropout rate
(35%), comparisons were made between the dogs
receiving levetiracetam during the first treatment
(n = 18) and those receiving placebo during the first
treatment (n = 10). Although a significant decrease in
weekly seizure frequency compared to baseline was
identified for dogs receiving levetiracetam, the reduction
in seizures was not significant when compared to pla-
cebo. There was no statistical difference in the number
of dogs classified as responders with levetiracetam
administration (56%) compared to placebo (30%).
A retrospective evaluation of dogs treated at an epi-
lepsy referral center described response rates to succes-
sively administered antiepileptic drugs.101 In this study,
32 dogs were given a third-line drug after failure to
respond to phenobarbital and bromide in combination,
27 of which were treated with levetiracetam. Over one-
third (38.5%) of dogs responded to the third-line drug,
with a 50% or greater decrease in seizure frequency,
but none of the treated dogs became seizure-free. How-
ever, it was not specified how many of these responders
were being treated with levetiracetam versus another
third-line drug.
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Zonisamide
Overall, the efficacy of zonisamide to decrease seizure
frequency by ≥50% in 23 epileptic dogs with generalized
seizures has been reported to be 58–80% when used as an
adjunctive antiepileptic medication.49,50 The 80% efficacy
refers to the first 4 months of zonisamide treatment.50
An open-label, noncomparative study including 12 idio-
pathic epileptic dogs poorly controlled with phenobarbi-
tal alone or in combination with bromide or other AEDs
or both and given zonisamide at a mean dosage of
8.9 mg/kg q12h, reported a median decrease in seizure
frequency (when comparing ≥8 weeks before and after
treatment initiation) of 84.5% (range, 54.8–100%; mean,
81.3%) in 7 (58%) dogs.49 Two of these 7 dogs became
seizure-free. Concurrently administered AEDs including
phenobarbital, bromide, felbamate, or clorazepate could
be decreased in dosage or discontinued in all 7 respon-
ders to zonisamide. The mean decrease in phenobarbital
dosage was 92.2%. The remaining 5 dogs (42%) experi-
enced a median increase in seizure frequency of 52.6%
(range 7.4–100%). All 12 dogs in this study experienced
generalized seizures, and 2 of them also had focal sei-
zures.49 The mean and median follow-up times after zon-
isamide administration were 33.5 weeks and 37 weeks,
respectively (range, 8–71 weeks). In all dogs, the PO
dosage of zonisamide was adjusted to achieve serum con-
centrations between 10 and 40 lg/mL. There were no sig-
nificant differences between serum zonisamide
concentrations in responders versus nonresponders for
either trough or peak concentrations.49
Another open-label, non-comparative study included
11 idiopathic epileptic dogs with generalized seizures
poorly responsive to phenobarbital, bromide, or both
and treated with zonisamide at a dosage of 10 mg/kg.50
Zonisamide was administered as adjunctive treatment in
10 dogs and as monotherapy in 1 dog that developed
phenobarbital-induced hematologic abnormalities. Sei-
zure frequency during the 4 months before and after
zonisamide treatment was compared. Eight of the 10
dogs (80%) given zonisamide as adjunctive treatment
had a median decrease in seizure frequency of 82.7%
(range, 58–100%) during the 4 months after zonisamide
treatment was initiated. However, seizure frequency
increased in 3 of these 8 dogs after long-term follow-up
(7–17 months). The dog on zonisamide monotherapy
experienced a seizure reduction of 100% with a 17-
month follow-up. The remaining 2 dogs included in the
study had seizure reductions of 14% and 25%, respec-
tively. Seizure duration and severity (eg, single seizures
instead of cluster seizures or status epilepticus)
decreased in 2 dogs. The dose of phenobarbital, bro-
mide or both could be decreased in 7 dogs without sub-
sequent impairment of seizure control.50
What Alternative Nonpharmacologic Treatments
Are Available?
Vagal Nerve Stimulation
Vagal nerve stimulation (VNS) involves surgical
implantation of a pacemaker-like device that delivers
repetitive electrical stimulation to the left cervical vagus
nerve and is now approved for use in people of all ages
and seizure types. The mechanism by which VNS exerts
its antiepileptic effect is not completely understood, but
it is believed that stimulation of afferent vagal fibers
influences brain activity by modulation of noradrenergic
and cholinergic synaptic transmission in people102,103
and dogs.104 Approximately, half of humans treated
with VNS will experience a positive response, with
a > 50% decrease in seizure frequency with a positive
correlation with efficacy with duration of treatment.105
Preclinical studies evaluating VNS as a treatment for
seizures performed in normal animals first demonstrated
that intermittent stimulation of the left cervical vagus
trunk could effectively prevent experimentally induced
seizures in dogs.106 A randomized, placebo-controlled,
crossover study evaluating the use of VNS in 10 dogs
with medically refractory idiopathic epilepsy found no
significant difference in seizure frequency, severity, or
duration between treatment and control groups over the
course of the 12-week study, but a 34% significant
decrease in seizure frequency was observed in the last
4 weeks of treatment.107
Dietary Alteration Treatment
The most well-known dietary treatment for human
epilepsy is the ketogenic diet, which is a high fat, low
protein, low carbohydrate diet designed to mimic the
biochemical changes of fasting to potentiate mitochon-
drial-dependent energy metabolism in neurons and inhi-
bition of glutamatergic metabolic pathways and synaptic
transmission.108,109 A randomized, double-blinded, con-
trolled trial evaluated the effectiveness of a high-fat, low-
carbohydrate diet compared to controls for seizures in
dogs with drug-resistant idiopathic epilepsy.110 The study
failed to identify a difference in seizure frequency
between the groups and 3 of 9 dogs fed the ketogenic diet
developed pancreatitis. In contrast, a medium chain
triglyceride (MCT)-based diet developed for the treat-
ment of cognitive dysfunction in dogs111 was evaluated
in dogs with idiopathic epilepsyin, a 6-month prospec-
tive, randomized, double-blinded, placebo-controlled
crossover dietary trial.112 Seizure frequency and monthly
seizure days were significantly lower in the 21 dogs finish-
ing the trial when on the test diet for 12 weeks as com-
pared to those on the placebo diet.
A recent, randomized, single-blinded, controlled
crossover trial evaluated the effects of omega-3 fatty
acid supplementation in 15 dogs with idiopathic epi-
lepsy and did not identify any difference in seizure fre-
quency or severity between the treatment and placebo
groups.113
Acupuncture
A recent evidence-based assessment of published ran-
domized controlled trials concluded that the current
available information does not support the use of
acupuncture in the treatment of epilepsy in people.114
Gold bead implants in 5 dogs with drug-resistant epi-
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lepsy for 6 months identified initial seizure frequency
improvement in all dogs but relapse of seizures in 2
dogs.115 An uncontrolled study with minimal study
design details of 40 dogs with idiopathic epilepsy
reported that 50% of dogs could be taken off all medi-
cation after receiving gold bead implantation, with 20
dogs having recurrent epileptic seizures, 10 dogs treated
with decreased AED dosage, and 10 dogs having no
response. A controlled open-label study evaluating 7
drug-na€ıve and 8 AED-treated dogs before and after
gold bead implants116 reported a 38.7% decrease in
mean seizure frequency for all dogs. No change in EEG
recordings in acupuncture-treated dogs was reported.117
Homeopathy
Homeopathic remedies most frequently used in
humans with epilepsy include silicea, cuprum, caus-
ticum, hyosciamus, Aethus cynapium, Agaricus muscari-
cus, Absinthium, Artemisia absinthium, stramonium, and
Cicuta virosa. Evidence to support the use of these
treatments currently is lacking.118,119
What are the Guidelines for Success and Quality
of Life Parameters?
The most important outcome measure of a chronic
medical condition such as epilepsy is quality of life
(QOL). For dogs, QOL is reflected not only by the
degree of therapeutic success but also by maintaining a
high QoL while living with epilepsy. The determination
of QoL is heavily influenced by the burden placed on
the household members as owners. Owners will choose
euthanasia if the emotional stress, psychosocial chal-
lenges, economic burden, or some combination of these
associated with having an epileptic dog in the house-
hold exceeds the expectations of the owner. Dogs with
epilepsy have been reported to have an increased risk of
premature death as a result of euthanasia.1,120,121 Sev-
eral factors may influence therapeutic success, in partic-
ular seizure etiology. A recent study investigating dogs
with idiopathic and structural epilepsy separately, found
that the median life span for dogs with idiopathic epi-
lepsy was not decreased when compared with the med-
ian life span of dogs in general, whereas the median life
span for dogs with structural epilepsy was significantly
reduced.122 The poor prognosis of structural epilepsy
reflects its etiology in which epileptic seizures are pro-
voked by confirmed intracranialcerebral pathology.
Breed also may influence outcome because certain
breeds (eg, Labrador retriever, Belgian shepherd) expe-
rience mild epilepsy with good outcome,123,124 whereas
other breeds (eg, Border collie, Australian shepherd)
suffer from a more aggressive form of epilepsy, and
may experience a more unfavorable outcome.125,126 Fur-
thermore, the tendency to develop cluster seizures or
status epilepticus has been found to negatively influence
outcome in dogs with epilepsy.127,128
Overall, the owners’ perspectives regarding the overall
impact of epilepsy on the household will determine if the
epileptic dog will survive with epilepsy or not. Quality of
life of epileptic dogs and the epilepsy burden on the
household have been investigated in a few studies,1,2,129
but these are difficult to assess objectively because owner-
based questionnaires addressing issues that will influence
a potential decision of euthanasia form the basis of such
investigations. To date, no standardized validated QOL
questionnaires exist for dogs with epilepsy.
Measures of the epilepsy burden on families should
include questions regarding restrictions on the owner’s
and household’s life, and frustrations over caring for a
dog with epilepsy, as well as emotional stress and anxi-
ety experienced in the household. Ultimately, economic
considerations and intrahousehold disagreements
regarding QOL of living with an epileptic dog factor
heavily in the decision to euthanize. The goal is to aid
owners in the decision-making process on QOL as it
pertains to themselves and their epileptic pets.
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